Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

Telaprevir (Incivek) Approved for Hepatitis C

On May 23 the U.S. FDA approved Vertex's HCV protease inhibitor telaprevir (brand name Incivek), the second direct-acting hepatitis C drug launched this month.

Read more:

Boceprevir (Victrelis) Approved for Hepatitis C

The U.S. FDA on May 13 approved the HCV protease inhibitor boceprevir (brand name Victrelis), the first direct-acting hepatitis C drug. alt

Read more:

Boceprevir for HCV Wins Unanimous FDA Committee Recommendation

FDA Antiviral Drugs Advisory Committee voted 18-0 to recommend approval of protease inhibitor boceprevir (Victrelis) for people with hard-to-treat HCV genotype 1.

Read more:

FDA Committee Unanimously Recommends Telaprevir (Incivek)

The FDA Antiviral Drugs Advisory Committee last week voted 18-0 to recommend approval of the HCV protease inhibitor telaprevir (Incivek) for people with genotype 1 chronic hepatitis C.

Read more:

EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status

The Vertex experimental protease inhibitor telaprevir, taken with pegylated interferon plus ribavirin, increased sustained response in people with all IL28B gene patterns, researchers reported at EASL 2011.

Read more: